If you read about Selank online, you will find a confident mechanism story: a tuftsin-derived heptapeptide that allosterically modulates GABA-A receptors, lifts BDNF, tunes immune signalling and changes the expression of dozens of genes in the brain. Almost all of that is true as written — and almost all of it comes from rats. The most recent Selank research to appear, a 2026 transcriptomics paper in Molecular Biology, is another rat study. Meanwhile the human record has not moved since 2015. That gap between an ever-richer molecular story and a frozen clinical one is the most useful thing to understand about this compound, and it is what this piece unpacks — along with what "is Selank legal in Australia" actually means in practice.

What is Selank, and why the mechanism talk is all transcriptomics

Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro: the immune tetrapeptide tuftsin with a Pro-Gly-Pro tail bolted on. That tail exists for a reason — it was added to slow peptidase attack, an implicit admission that the free peptide does not hang around in circulation for long. A compound that clears quickly but is claimed to produce effects lasting hours needs a durable downstream mechanism, and the Russian groups behind Selank went looking for one in gene expression rather than in receptor occupancy.

That choice shaped the entire evidence base. When you see "Selank changes 45 genes", you are reading a PCR array, not an outcome.

The 2026 paper: 118 genes in a rat stroke model

The newest entry is a RNA-seq study of Selank in early experimental cerebral ischaemia in rats, published in Molecular Biology (2026). Researchers profiled the frontal cortex 4.5 hours after ischaemia onset and reported 118 differentially expressed genes versus saline, using a threshold of >1.5-fold change and adjusted p < 0.05.

Worth stating plainly: this is a single preclinical study, in one species, in a stroke model — not anxiety, not healthy volunteers, and not replicated by an independent group. A differentially expressed gene list is a hypothesis generator. It tells you the peptide is doing something measurable in tissue; it does not tell you a person feels or functions differently.

"Allosteric GABA-A modulator": what that claim actually rests on

This is the single most repeated line about Selank, and it traces to two strands of work.

The gene-expression strand

Volkova and colleagues (Frontiers in Pharmacology, 2016) measured an 84-gene neurotransmission panel in rat frontal cortex after Selank or GABA. Forty-five genes changed at one hour and 22 at three hours, and the pattern after Selank resembled the pattern after GABA itself. The authors' interpretation was that Selank acts on the GABAergic system indirectly — consistent with allosteric modulation rather than direct receptor agonism.

The binding strand

Vyunova and co-workers (Neurochemical Journal, 2014) ran radioligand work with [³H]GABA on nerve-cell plasma membranes, testing Selank and its short fragment Arg-Pro-Gly-Pro. Prior intranasal Selank altered the number of specific GABA binding sites without changing receptor affinity. That is a reasonable basis for the word "allosteric" — but note what it is not. Nobody has published a benzodiazepine-site binding constant for Selank, because Selank does not appear to occupy that site. A third strand, from 2001, showed Semax and Selank inhibiting enkephalin-degrading enzymes in human serum — an ex vivo biochemistry result, not a clinical mechanism.

So "works like a benzo without the downsides" is a marketing sentence, not a pharmacology one. The receptor-level evidence says the opposite: a different, indirect, and largely inferred mode of action. More on the mechanism and its limits on the Selank profile page.

Why gene expression is not an outcome

Three practical reasons to discount gene-list findings when judging whether a compound works in humans:

  • Direction is not benefit. An upregulated receptor subunit transcript can reflect compensation as easily as therapeutic action.
  • Transcript is not protein. mRNA changes at one hour frequently fail to appear as protein or function.
  • Model is not indication. A stroke model tells you little about mild anxiety in an outpatient.

The human evidence for Selank remains three small Russian trials, the newest from 2015, underpinning its registration in Russia for mild anxiety. No large Western randomised controlled trial has been completed. That is the sentence the mechanism literature keeps getting used to paper over.

Selank Australia: is Selank legal in Australia?

The Australian position is specific and often misread. Selank is unscheduled in the Poisons Standard — it has no entry, which is not the same as approval. It is an unapproved therapeutic good: it is not on the Australian Register of Therapeutic Goods, so it cannot lawfully be sold or advertised in Australia for a therapeutic purpose. Access, where it happens at all, runs through prescriber-controlled pathways such as the Special Access Scheme, Authorised Prescriber arrangements, or personal importation under strict conditions.

The TGA has issued explicit warnings about imported peptide products supplied in unmarked or code-labelled vials, noting that non-compliant goods can be seized and destroyed and that fines or proceedings may follow. That is a labelling and identity risk as much as a legal one — with an unapproved compound, nobody has verified what is in the vial.

For athletes: Selank is not named on the WADA 2026 Prohibited List. That is not a green light. Sport Integrity Australia is the only appropriate source of advice for anyone in a tested sport, given how the non-approved-substances category (S0) is applied.

We track the wider space at /peptides and send a plain-English update when something genuinely changes — you can join the free list.

What would actually move the evidence

A single adequately powered, placebo-controlled trial in generalised anxiety, run outside Russia, with a validated primary endpoint and published protocol. Until that exists, every new rat transcriptome adds detail to a mechanism for an effect that has never been robustly demonstrated in humans. That is the honest state of Selank research in 2026.

FAQ

What is Selank used for?

Selank is registered in Russia as a treatment for mild anxiety and is used there intranasally; elsewhere it has no approved therapeutic use. Claimed nootropic and immune applications rest on preclinical work, not completed human trials.

Is Selank legal in Australia?

Selank is unscheduled in the Poisons Standard but is an unapproved therapeutic good — it is not on the ARTG, so it cannot be lawfully sold or advertised for therapeutic use in Australia, and the TGA has warned about imported unapproved peptide products.

Does Selank work like a benzodiazepine?

No. The evidence points to indirect, allosteric effects on the GABAergic system in rats, with no published binding at the benzodiazepine site, and it has never been compared head-to-head with a benzodiazepine in an adequately controlled human trial.

Is there any new Selank research in 2026?

Yes, but it is preclinical: a 2026 RNA-seq study in Molecular Biology reported 118 differentially expressed genes in rat frontal cortex during early cerebral ischaemia. The newest human data remain three small Russian trials, the latest from 2015.

Sources

This article is information only, not medical advice. Selank is not approved by the TGA and is an unapproved therapeutic good in Australia; retatrutide.net.au is independent and does not sell or source any compound.